More detailed clinical studies are required to clarify the possible role of TIM-3 in CLL pathogenesis and its association with cases of leukemia relapse, response to standard therapeutic agents and molecular prognostic factors of CLL. The gene discussed is HAVCR2; the disease is B-cell chronic lymphocytic leukemia.